// App-Quantinova.ai

BSH2020‐PO‐143 : Effects of luspatercept on iron overload and impact on responders to luspatercept: results from the BELIEVE Trial

Researchers

Presenter

  • J. Porter

Principal Investigators

  • E. Drasar

  • Q. A. Hill

  • V. Viprakasit

  • A. Taher

  • P. Georgiev

  • K. H. M. Kuo

  • T. Coates

  • E. Voskaridou

  • H. K. Liew

  • I. Pazgal-Kobrowski

  • S. Perrotta

  • A. Khelif

  • A. Lal

  • A. Kattamis

  • A. Laadem

  • J. K. Shetty

  • P. G. Linde

  • O. Hermine

  • A. Piga

  • M. D. Cappellini

Medical Centers

  • University College London, University College London Hospi

  • Department of Rheumatology, Whittington Hospital NHS Trust, London, UK

  • StJamess University Hospital, Leeds, UK

  • Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

  • Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon

  • St George University Hospital for Active Treatment

  • Medical University Plovdiv, Plovdiv, Bulgaria

  • Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Division of Hematology, Department of Medicine, University of Toronto,Toronto, ON,Canada

  • Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA

  • UCLA School of Medicine, Los Angeles, CA

  • Thalassemia and Sickle Cell Center ,Laiko General Hospital,Athens,Grecia

  • Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia

  • Comprehensive Center of Thalassemia,Rabin Medical Center, Beilinson Hospital,Petah Tikva,Israel

  • Università della Campania,Luigi Vanvitelli,Caserta,Italy

  • Farhat Hached University Hospital, Sousse, Tunisia

  • University of California San Francisco Benioff Children's Hospital,Oakland,United States

  • First Department of Radiology, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece

  • Bristol-Myers Squibb, Summit, NJ

  • Celgene International Sarl, Boudry, Switzerland

  • Acceleron Pharma, Cambridge, MA

  • Imagine Institute

  • Department of Haematology, Tenon University Hospital, Assistance Publique Hopitaux de Paris, Paris, France

  • Dept of Clinical and Biological Sciences, University of Turin, Turin, Italy

  • Fondazione IRCCS Ca' Granda Maggiore Hospital, University of Milan, Milan, Italy

Locations

  • United Kingdom

  • Thailand

  • Lebanon

  • Bulgaria

  • Canada

  • United States

  • Greece

  • Malaysia

  • Israel

  • Italy

  • Tunisia

  • Switzerland

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Hemochromatosis

Biomarkers

  • Red Blood Cells

Drug/Treatment

  • luspatercept

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02604433

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved